The JN.1 variant (BA.2.86.1.1), arising from BA.2.86.1 with the S:L455S substitution, showed increased fitness and outcompeted the previous dominant XBB lineage by the beginning of 2024.1 JN.1 subsequently diversified, leading to the emergence of desce...
Elimination of leprosy as a public health problem (prevalence of fewer than one leprosy case per 10 000 people) was attained in the majority of countries by 2010. Still, this neglected tropical disease is found in over 120 countries, with more than 200...
For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for...
In 1948, the pioneering study that introduced streptomycin as the first treatment for tuberculosis (TB) was published, but the rapid onset of drug-resistant strains restricted the long-term benefit of streptomycin monotherapy.1 This led to the explorat...
Compared with other SARS-CoV-2 variants, BA.2.86 and the JN.1 sublineage were less sensitive to vaccine-induced immune protection from the XBB.1.5 updated COVID-19 vaccine; however, we found no evidence that infection with BA.2.86 or JN.1 resulted in i...
The constant transformation of SARS-CoV-2 poses considerable challenges for COVID-19 vaccine programmes. Since it was first detected in August, 2023, the SARS-CoV-2 omicron subvariant BA.2.86, and in particular the sublineage JN.1, have rapidly spread ...
The Pan-Lassa RDT is not currently recommended as a diagnostic or screening tool for suspected Lassa fever cases. Marked improvement in sensitivity and user friendliness is needed for the RDT to be adopted clinically. There remains an urgent need for b...
Lassa virus (LASV) is a high-consequence pathogen endemic to west Africa that causes annual outbreaks with substantial mortality. Besides transmission from the rodent reservoir to humans, human-to-human transmission can occur through contact with blood...
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 and 1 000 000 individuals, increasing with every ren...
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There are ethical reasons to transition to a single-dose str...
Syphilis is a major global cause of fetal loss, stillbirth, neonatal death, and symptomatic disease in neonates and infants.1,2 In 2020, the global incidence of congenital syphilis was 425 cases per 100 000 livebirths, 8·5 times higher than elimination...
Ferrés M, Martínez-Valdebenito C, Henriquez C, et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7—In ...
Antimicrobial resistance in Neisseria gonorrhoeae is an urgent global health threat. Ceftriaxone is the only remaining option for empirical monotherapy of gonococcal infections. The prevalence of ceftriaxone resistance in N gonorrhoeae is highest in th...
Antimicrobial resistance in Neisseria gonorrhoeae is an urgent global health threat. Ceftriaxone is the only remaining option for empirical monotherapy of gonococcal infections. The prevalence of ceftriaxone resistance in N gonorrhoeae is highest in th...
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation.
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation.